Current Hematologic Malignancy Reports

, Volume 4, Issue 4, pp 189–195

Vaccination strategies in follicular lymphoma


DOI: 10.1007/s11899-009-0025-2

Cite this article as:
Kannan, S. & Neelapu, S.S. Curr Hematol Malig Rep (2009) 4: 189. doi:10.1007/s11899-009-0025-2


Follicular lymphoma is one of the most immuneresponsive cancers. The clonal tumor immunoglobulin expressed on the surface of malignant B cells, termed idiotype, has been used as a tumor-specific antigen in therapeutic vaccination strategies for follicular lymphoma and other B-cell malignancies. A number of phase 1 and phase 2 clinical trials have established the safety and immunogenicity of idiotype vaccine in follicular lymphoma. Three randomized, double-blind, controlled phase 3 clinical trials have recently been completed to definitively evaluate the clinical benefit of idiotype vaccine in follicular lymphoma. This review focuses on the results of these idiotype vaccine trials and discusses poten tial strategies to enhance the efficacy of vaccines in the future.

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Department of Lymphoma and MyelomaThe University of Texas M. D. Anderson Cancer CenterHoustonUSA